



University of California San Francisco,  
USA

Ruth.Malone@ucsf.edu

Cite this as: *BMJ* 2024;385:q950

<http://dx.doi.org/10.1136/bmj.q950>

# Stop tobacco industry sponsorship of continuing medical education

This malign industry must not be allowed to influence clinicians' learning

Ruth E Malone *professor*

In a troubling development for tobacco control, Medscape, a continuing education website for health professionals, was recently discovered to be promoting a series on smoking cessation sponsored by tobacco company Philip Morris International (PMI).<sup>1</sup> Observers will note the bizarre incongruity of education programmes for doctors being funded by a tobacco giant whose products are estimated to kill over a million people a year,<sup>2</sup> yet such initiatives are all part of tobacco companies' most recent attempts to rebrand themselves to ensure their continued financial health.

PMI, with the second largest market share of the global cigarette market,<sup>3</sup> claims to be transitioning to the "health and wellness" sector, building on its acquisition of inhaler company Vectura in 2021.<sup>2,4</sup> After *The BMJ's* Medscape investigation was published, evidence emerged that other courses sponsored by PMI—all focused on its version of "harm reduction"—were being offered or planned in South Africa, the Middle East, and possibly other parts of the world.<sup>5</sup>

After an outcry led by clinicians and health professional organisations about course content (such as quitting smoking being omitted from the suggested options for patients concerned about how to reduce their lung cancer risk), Medscape removed the content and now claims to have established a policy against accepting any tobacco industry funding for educational programmes.<sup>5</sup>

However, the company also claims that the content complied fully with accreditation standards set by the Accreditation Council for Continuing Medical Education.<sup>6</sup> If true, the standards clearly need to be upgraded, urgently.

## Vested interests

So what is wrong with a tobacco company funding courses for doctors and nurses? First, even if course content is clearly labelled as funded by Philip Morris International, many health professionals, especially those in countries where the visibility of tobacco giants is low, may be unaware that PMI is a tobacco company with a vested interest in promoting its own non-cigarette nicotine products, and therefore the risk of bias in funded content is high. A rich literature on commercial bias in medical research and education already exists, primarily focused on the influence of drug and medical device manufacturers.<sup>7-10</sup> As a leading researcher on the topic noted, product promotion through industry funded continuing medical education (CME) is unregulated, and most health professionals cannot detect covert commercial bias, yet "industry-funded

CME is always related to business lines or products of sponsors."<sup>11</sup>

Second, involvement in "harm reduction" is part of the tobacco industry's ongoing efforts to portray itself as "transformed," now offering a solution to the problems it created.<sup>12-14</sup> While harm reduction is a legitimate public health approach, the tobacco industry's version falsely suggests that harm reduction can be achieved only by using new nicotine products such as e-cigarettes and heated tobacco products—products ostensibly targeted only at people who already smoke. Yet no tobacco company has applied for regulatory approval for these products as smoking cessation devices, and tobacco companies continue to interfere in governments' efforts to implement effective, evidence based tobacco control policies that reduce smoking and thus reduce harm.<sup>15</sup>

The tobacco industry's harm reduction narrative is also a direct challenge to the rising interest globally in planning for a commercial tobacco endgame.<sup>16</sup> The endgame narrative calls for governments to develop and implement more aggressive policy measures to reduce access, attractiveness, affordability, and availability of tobacco products, up to and including phasing out sales of some or all products, with the ultimate goal of ending the tobacco epidemic. A financially healthy tobacco industry is fundamentally incompatible with that goal.

In contrast, the industry version of harm reduction seeks to undermine the idea of an endgame and assert instead that more "choice" of addictive products is the answer, nicotine is virtually benign, and addiction relatively harmless. For example, PMI markets its heated tobacco product IQOS as "smoke-free,"<sup>17</sup> a controversial characterisation of an inhaled tobacco product that independent studies suggest is not, in fact, smoke-free and may actually be more harmful than claimed.<sup>18</sup>

Health professionals, health leaders, and their societies and professional organisations must demand that the bodies accrediting continuing medical education for clinicians enact policies banning content sponsored by tobacco affiliated organisations. The reasons for doing so will be obvious to most, and they are similar to the reasons why many reputable journals, including *The BMJ*, will no longer consider research papers funded by the tobacco industry.<sup>19</sup> Tobacco companies should have no role in providing education for health professionals.

Further, health professional and patient organisations should caution their members to be aware that the tobacco industry is attempting to influence patient care in favour of its products. Medical education at

all levels should give learners a clear understanding of the commercial determinants of health so that all clinicians are prepared to critically examine sponsors, authors, and content of CME related to tobacco harms.

Although it is among the largest, Medscape is not the only company offering CME, and PMI may not be the only tobacco company working to influence health professionals through this channel. If other similar offerings are discovered, they should be widely publicised on professional networks and wider media, and the relevant educational providers notified that tobacco industry sponsorship is unacceptable. The tobacco industry cannot be allowed to influence medical education, health practitioners, or patient care in this way as it desperately seeks to secure its future profits.

Competing interests: *The BMJ* has judged that there are no disqualifying financial ties to commercial companies. The author declares the following other interests: Within the past five years I have received grant funding from the US National Cancer Institute, National Institutes of Health, the California Tobacco-Related Disease Research Program (research funds derived from the state tax on cigarettes), and the California Tobacco Control Program. I own one share of stock in each of three tobacco companies, including PMI, for research and advocacy purposes. Since 1997, I have been a faculty employee of the University of California, San Francisco. I am semi-retired and receive a pension from the university. Further details of The BMJ policy on financial interests are here: <https://www.bmj.com/sites/default/files/attachments/resources/2016/03/16-current-bmj-education-coi-form.pdf>.

Provenance and peer review: Commissioned; not externally peer reviewed.

- 1 Boytchev H. Exclusive: Outcry as Philip Morris International funds smoking cessation courses on Medscape. *BMJ* 2024;385:. doi: 10.1136/bmj.q830 pmid: 38594042
- 2 Capstick TGD, Hopkinson NS. Adapting inhaled medication practice in COPD and asthma to avoid funding the tobacco industry. *Int J Chron Obstruct Pulmon Dis* 2021;16:-23. doi: 10.2147/COPD.S337066 pmid: 34729008
- 3 Trenda E. Philip Morris International—statistics and facts. *Statista* 2024 Mar 18 <https://www.statista.com/topics/4633/philip-morris/>.
- 4 Hopkinson N. Philip Morris and Vectura—an invasive growth. *Tobacco Control* blog, 15 Nov 2021. <https://blogs.bmj.com/tc/2021/11/15/philip-morris-and-vectura-an-invasive-growth/>.
- 5 Boytchev H. Medscape caves in on courses funded by tobacco giant, while medics fear global push by Philip Morris into medical education. *BMJ* 2024;385:.
- 6 Accreditation Council for Continuing Medical Education. Standards for integrity and independence in accredited continuing education. <https://www.accme.org/accreditation-rules/standards-for-integrity-independence-accredited-ce>. 2020.
- 7 Rodwin MA. Drug advertising, continuing medical education, and physician prescribing: a historical review and reform proposal. *J Law Med Ethics* 2010;38:-15. doi: 10.1111/j.1748-720X.2010.00534.x pmid: 21105944
- 8 Parker L, Grundy Q, Bero L. Interpreting evidence in general practice: bias and conflicts of interest. *Aust J Gen Pract* 2018;47:-40. doi: 10.31128/AJGP-12-17-4432 pmid: 29966180
- 9 Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome: systematic review with meta-analysis. *Intensive Care Med* 2018;44:-12. doi: 10.1007/s00134-018-5293-7 pmid: 30132025
- 10 Grundy Q, Millington A, Cussen C, Held F, Dale CM. Promotion or education: a content analysis of industry-authored oral health educational materials targeted at acute care nurses. *BMJ Open* 2020;10:e040541. doi: 10.1136/bmjopen-2020-040541 pmid: 33247018
- 11 Fugh-Berman A. Industry-funded medical education is always promotion. *BMJ* 2021;373:. doi: 10.1136/bmj.n1273 pmid: 34088736
- 12 Edwards R, Hoek J, Karreman N, Gilmore A. Evaluating tobacco industry 'transformation': a proposed rubric and analysis. *Tob Control* 2022;31:-21. doi: 10.1136/tobaccocontrol-2021-056687 pmid: 35241605
- 13 Tobacco Tactics. Harm reduction. 2022. <https://tobacotactics.org/article/harm-reduction/>
- 14 Cohen JE. Big tobacco is trying to hide its greed behind 'harm reduction.' *The Hill* 2024 Mar 17. <https://thehill.com/opinion/healthcare/4524685-big-tobacco-is-trying-to-hide-its-greed-behind-harm-reduction/>
- 15 Global Center for Good Governance in Tobacco Control. *Global tobacco industry interference index 2023*:<https://globaltobaccoindex.org/report-summary>
- 16 McDaniel PA, Smith EA, Malone RE. The tobacco endgame: a qualitative review and synthesis. *Tob Control* 2016;25:-604. doi: 10.1136/tobaccocontrol-2015-052356 pmid: 26320149
- 17 Philip Morris International. Our smoke-free products. <https://www.pmi.com/our-business/smoke-free-products>
- 18 Uguna CN, Snape CE. Should IQOS emissions be considered as smoke and harmful to health? a review of the chemical evidence. *ACS Omega* 2022;7:-24. doi: 10.1021/acsomega.2c01527 pmid: 35811880

19 Malone RE. Changing Tobacco Control's policy on tobacco industry-funded research. *Tob Control* 2013;22:-2. doi: 10.1136/tobaccocontrol-2012-050874 pmid: 23239401